Chief Scientific Officer · Aclaris Therapeutics, Inc. (ACRS)

Joseph Monahan

A named executive officer of Aclaris Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,255,344

Salary $374,400Stock awards $509,100

FY2022: $2,822,982

5th of 5 named executive officers at Aclaris Therapeutics by FY2023 total.

5 named officers on file for Aclaris Therapeutics, FY2023

Joseph Monahan’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • ACRS’s disclosed peer group of 43 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aclaris Therapeutics’s whole pay program stands against its peers

  • Aclaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joseph Monahan’s full pay file as a PDF — free

More than this page: up to 10 years of Joseph’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joseph Monahan compensation by year

Aclaris Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Aclaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$350,000$420,000$374,400
Bonus$0$0$0
Stock awards$4,812,000$652,878$509,100
Option awards$0$1,570,083$1,253,812
Non-equity incentive$154,700$168,000$104,832
Pension and deferred compensation$0$0$0
All other$10,605$12,021$13,200
Total$5,327,305$2,822,982$2,255,344

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 25, 2024, accession 0001558370-24-005677, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-24-005677. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

$5.3M
$2.8M
$2.3M
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU100,000$105,000—
RSU32,775$34,414—
RSU30,000$31,500—
RSU12,500$13,125—
Option153,100—$16.97
Option114,825—$14.94

Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

20 Form 4 lines since the FY2023 proxy (filed April 25, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-03-01Exercise or conversion derivative—10,925$0.0010,925
2025-03-01Tax withholding—27,258$1.99265,662
2025-03-01Exercise or conversion—50,000—281,995
2025-03-01Exercise or conversion—10,925—292,920
2025-03-01Exercise or conversion derivative—50,000$0.000
2025-02-03Grant or award derivative—83,900$0.0083,900
2025-02-03Grant or award derivative—293,500$0.00293,500
2025-02-01Tax withholding—11,317$2.48231,995

The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Aclaris Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Douglas ManionFormer Chief Executive Officer and President$7,157,681
Gail CawkwellFormer Chief Medical Officer$2,403,312
Kevin BalthaserChief Financial Officer$2,344,432
James LoeropChief Business Officer$2,332,912
Joseph Monahan · this pageChief Scientific Officer$2,255,344

The full Aclaris Therapeutics compensation record

free company brief

This page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aclaris Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Monahan's compensation dossier · One-time report. No refunds.